- Home
- FLUX vs AKTX Comparison
FLUX vs AKTX Comparison
Compare FLUX & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLUX
- AKTX
- Stock Information
- Founded
- FLUX N/A
- AKTX N/A
- Country
- FLUX United States
- AKTX United States
- Employees
- FLUX N/A
- AKTX N/A
- Industry
- FLUX Industrial Machinery/Components
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- FLUX Miscellaneous
- AKTX Health Care
- Exchange
- FLUX Nasdaq
- AKTX Nasdaq
- Market Cap
- FLUX 30.0M
- AKTX 35.7M
- IPO Year
- FLUX N/A
- AKTX N/A
- Fundamental
- Price
- FLUX $1.49
- AKTX $0.82
- Analyst Decision
- FLUX Strong Buy
- AKTX Strong Buy
- Analyst Count
- FLUX 2
- AKTX 1
- Target Price
- FLUX $6.00
- AKTX $5.00
- AVG Volume (30 Days)
- FLUX 140.6K
- AKTX 85.8K
- Earning Date
- FLUX 05-08-2025
- AKTX 08-13-2025
- Dividend Yield
- FLUX N/A
- AKTX N/A
- EPS Growth
- FLUX N/A
- AKTX N/A
- EPS
- FLUX N/A
- AKTX N/A
- Revenue
- FLUX $63,074,000.00
- AKTX N/A
- Revenue This Year
- FLUX $10.96
- AKTX N/A
- Revenue Next Year
- FLUX $12.78
- AKTX N/A
- P/E Ratio
- FLUX N/A
- AKTX N/A
- Revenue Growth
- FLUX N/A
- AKTX N/A
- 52 Week Low
- FLUX $1.15
- AKTX $0.57
- 52 Week High
- FLUX $3.48
- AKTX $3.85
- Technical
- Relative Strength Index (RSI)
- FLUX 39.70
- AKTX 41.35
- Support Level
- FLUX $1.63
- AKTX $0.57
- Resistance Level
- FLUX $1.88
- AKTX $1.01
- Average True Range (ATR)
- FLUX 0.15
- AKTX 0.07
- MACD
- FLUX -0.02
- AKTX -0.01
- Stochastic Oscillator
- FLUX 4.44
- AKTX 56.42
About FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.